

Researchers Find Eight New Unique Gene Mutations in Patients with Hereditable Heart Muscle Disease

SALT LAKE CITY, UT, USA, April 17, 2019 /EINPresswire.com/ -- In a new study from the Intermountain Healthcare Heart Institute in Salt Lake City, researchers have identified eight new gene mutations that may cause or contribute to idiopathic dilated cardiomyopathy, a form of heart disease not caused by known external influences, such as high blood pressure, obesity, smoking, or diseased coronary arteries.

For at least 40 percent of these patients, the disease has an underlying genetic cause that leads to the muscle in the major pumping chamber of the heart (left ventricle) being too weak and thin to function properly, causing heart failure.



Intermountain Healthcare Heart Institute researchers have identified eight new gene mutations that may cause or contribute to idiopathic dilated cardiomyopathy.

"Although many mutations contributing to non-ischemic dilated cardiomyopathy have been identified, there remains a large gap in our knowledge of its heritability. The more we can learn

٢

If it's passed on in families, we'll be able to identify those who might be at risk for developing heart disease and work to prevent it, diagnose it, and begin treatment earlier." Dr. Jeffrey Anderson,

Intermountain Healthcare Heart Institute about what's causing the condition, the better we can identify and treat it," said Jeffrey L. Anderson, MD, principal investigator of the study, and a researcher at the Intermountain Healthcare Heart Institute. "If it's passed on in families, we'll be able to identify those who might be at risk for developing heart disease and work to prevent it, diagnose it, and begin treatment earlier."

Findings from the study were presented at the American College of Cardiology's Annual Scientific Session in New Orleans last month.

A quarter to one-third of idiopathic dilated cardiomyopathy patients will need a mechanical support

device, a heart transplant, or will die within five years, Dr. Anderson noted, so this is a very serious condition.

In the study, researchers looked at genetic samples of 231 patients with idiopathic dilated cardiomyopathy, evaluated in an Intermountain Medical Center Specialty Clinic who volunteered to enter blood samples into the Intermountain Healthcare INSPIRE Registry and DNA Bank, which is the system's collection of biological samples, clinical information, and laboratory data

from consenting patients who are diagnosed with any of a number of healthcare-related conditions.

In collaboration with Intermountain's Precision Genomics laboratory, researchers sequenced patients' DNA, focusing on the TITIN (TNN) gene, which codes the body's largest protein.

"That protein acts as a spring in your heart muscle," said Dr. Anderson. "It enhances the passive elasticity of the muscle and also limits how much you can stretch it."

Previous research has already found variants of TTN in patients with idiopathic dilated cardiomyopathy, but the story has been incomplete.

Now, in this new study, Intermountain researchers identified 24 patients with TTN variants, and eight of those variants hadn't been seen or documented before. They also confirmed the presence of seven variants that had been discovered and reported previously. The new variants all are of the "truncating" variety, that is, they lead to a shortening of the protein and in doing so are predicted to cause the protein to malfunction in its role of maintaining the integrity of heart muscle function.

These new variants, Dr. Anderson said, still will require functional testing and clinical validation, but they likely will lead to further expansion of the known spectrum of genes that predispose to idiopathic dilated cardiomyopathy.

The addition of these variants to the current list of known pathological heart muscle protein mutations will help to close the still large gap in our knowledge of the heritability of heart muscle disease and in doing so can lead to earlier diagnosis and more effective prevention and treatment.

The study was funded by the Intermountain Foundation and an in-kind grant from Intermountain Precision Genomics.

Jess C. Gomez Intermountain Healthcare +1 801-718-8495 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2019 IPD Group, Inc. All Right Reserved.